XORTX Confirms Effective Date of Share Consolidation
Rhea-AI Summary
XORTX (NASDAQ: XRTX) confirmed a 1-for-5 share consolidation will take effect on April 6, 2026. According to the company, the consolidation received required approvals from the TSX Venture Exchange and Nasdaq.
The move replaces every five old common shares with one new common share and will adjust the company’s issued and outstanding share count on the effective date.
AI-generated analysis. Not financial advice.
Positive
- 1-for-5 consolidation set for April 6, 2026
- Received approvals from TSX Venture Exchange and Nasdaq
Negative
- Reduced public float may temporarily lower trading liquidity
News Market Reaction – XRTX
On the day this news was published, XRTX gained 3.67%, reflecting a moderate positive market reaction. Argus tracked a peak move of +19.0% during that session. Argus tracked a trough of -5.1% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $114K to the company's valuation, bringing the market cap to $3.23M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
XRTX gained 6.79% while peers showed mixed moves, with JAGX and TOVX up and QNRX and ENTO down, indicating a stock-specific reaction to the consolidation update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Meeting results | Negative | +8.0% | Shareholders approved items including a share consolidation resolution. |
| Mar 26 | Consolidation timing change | Negative | +8.0% | Company delayed effective date of the 1‑for‑5 share consolidation. |
| Mar 25 | Consolidation details | Negative | -9.7% | Announced 1‑for‑5 consolidation to address Nasdaq listing requirements. |
| Mar 24 | Consolidation approval | Negative | -0.8% | Shareholders approved up to a 5‑for‑1 share consolidation. |
| Mar 18 | Board nominees & financing | Positive | +6.5% | New director nominees proposed as condition of a significant financing. |
Recent news focused on the same 1-for-5 share consolidation has produced mixed price reactions, with some announcements sold off and others bid up, suggesting inconsistent trading responses to this corporate action.
Over March 2026, XORTX issued a sequence of announcements around its 1‑for‑5 share consolidation, from the initial proposal and shareholder approval on March 24 through detailed implementation terms and revised timing. These moves aim to address Nasdaq’s minimum bid requirement and maintain listing. Earlier in March, the company also pursued board changes linked to a potential financing. Today’s confirmation of an effective date on April 6, 2026 continues that consolidation timeline.
Market Pulse Summary
This announcement finalizes timing for XORTX’s 1‑for‑5 share consolidation, now set to take effect on April 6, 2026 with approvals from both exchanges. It follows a series of March updates around shareholder authorization and implementation details. Investors may weigh this corporate action against fundamentals, including a US$2,656,304 net loss in 2025 and an accumulated deficit of US$23,824,557. Future filings and clinical milestones will be key to monitor.
Key Terms
tsx venture exchange regulatory
nasdaq stock exchange regulatory
AI-generated analysis. Not financial advice.
CALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, further to its news release of March 26, 2026, the implementation of its share consolidation on the basis of one (1) new common share for every five (5) old common shares (the “Consolidation”) has received all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange and will occur on April 6, 2026.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications | |
| adavidoff@xortx.com | nick@alpineequityadv.com | |
| +1 403 455 7727 | +1 617 901 0785 | |
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, regulatory approvals, such as the TSXV; the ability to complete the Consolidation; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
